Press Release: Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Dow Jones
06 Feb

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

PR Newswire

BOSTON, Feb. 6, 2025

Financial release accessible online

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation $(HAE)$ announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information:

   -- Teleconference 
      link: https://register.vevent.com/register/BIda08929a4d56464eb33eccb945ef 
      985e 
 
   -- Once registration is completed, participants will receive a dial-in 
      number along with a personalized PIN to access the call. While not 
      required, it is recommended that participants join 10 minutes prior to 
      the event start. 
 
   -- A live webcast of the call can be accessed on Haemonetics' investor 
      relations website or via the following link: 
      https://edge.media-server.com/mmc/p/63jte4ra 

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.

Direct link to 3Q FY25 Earnings Release:

https://haemonetics.gcs-web.com/static-files/36134646-a371-4076-87b9-26673f9f10f3

A replay of the conference call and webcast will be available for one year beginning on February 6, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

 
Investor Contacts: 
Olga Guyette, Vice President-Investor   David Trenk, Manager-Investor 
Relations & Treasury                    Relations 
(781) 356-9763                          (203) 733-4987 
olga.guyette@haemonetics.com            david.trenk@haemonetics.com 
 
Media Contact: 
Josh Gitelson, Sr. Director-Global 
Communications 
(781) 356-9776 
josh.gitelson@haemonetics.com 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-year-2025-earnings-release-available-on-investor-relations-website-302368961.html

SOURCE Haemonetics Corporation

 

(END) Dow Jones Newswires

February 06, 2025 06:00 ET (11:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10